Relmada Therapeutics
Stock Forecast, Prediction & Price Target

Relmada Therapeutics Financial Estimates

Relmada Therapeutics Revenue Estimates

Relmada Therapeutics EBITDA Estimates

Relmada Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$0
 
N/A
$0
 
0%
$0
 
0%
Avg: $2.45M
Low: $2.45M
High: $2.45M
avg. 0%
Avg: $48.07M
Low: $48.07M
High: $48.07M
avg. 1855.27%
Avg: $109.3M
Low: $109.3M
High: $109.3M
avg. 127.36%
Avg: $289.7M
Low: $289.7M
High: $289.7M
avg. 165.05%
Net Income
 
% change YoY
$-125.75M
 
N/A
$-157.04M
 
-24.88%
$-98.79M
 
37.09%
Avg: $-119.74M
Low: $-133.03M
High: $-43.64M
avg. -21.20%
Avg: $-126.00M
Low: $-116.78M
High: $-33.10M
avg. -5.23%
Avg: $-58.24M
Low: $-58.24M
High: $-58.24M
avg. 53.77%
Avg: $12.79M
Low: $12.79M
High: $12.79M
avg. 121.96%
EBITDA
 
% change YoY
$-124.45M
 
N/A
$-156.44M
 
-25.70%
$4.91M
 
103.13%
Avg: $0
Low: $0
High: $0
avg. -100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
EPS
 
% change YoY
-$7.16
 
N/A
-$5.3
 
25.97%
-$3.28
 
38.11%
Avg: -$2.58
Low: -$4.42
High: -$1.45
avg. 21.34%
Avg: -$2.43
Low: -$3.88
High: -$1.1
avg. 5.91%
Avg: -$1.94
Low: -$1.94
High: -$1.94
avg. 20.28%
Avg: $0.43
Low: $0.43
High: $0.43
avg. 121.96%
Operating Expenses
 
% change YoY
$125.70M
 
N/A
$161.24M
 
28.27%
$103.70M
 
-35.68%
Avg: $0
Low: $0
High: $0
avg. -100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%

FAQ

What is Relmada Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 37.32% in 2025-2028.

We have gathered data from 3 analysts. Their low estimate is -133.03M, average is -119.74M and high is -43.64M.

What is Relmada Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 536.92% in 2025-2028.

We have gathered data from 4 analysts. Their low revenue estimate is $2.45M, average is $2.45M and high is $2.45M.

What is Relmada Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 42.37% in 2025-2028.

We have gathered data from 3 analysts. Their low earnings per share estimate is -$4.42, average is -$2.58 and high is $-1.45.

What is the best performing analyst?

In the last twelve months analysts have been covering Relmada Therapeutics stock. The most successful analyst is Andrea Tan.